Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119689 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL10250146 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2119875 | 0.83 | KMT2A (1.00) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2118123 | 0.83 | MEN1 (1.00) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2122421 | 0.83 | MEN1 (1.00) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2119864 | 0.80 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL2189346 | 0.78 | LMNA (0.85) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL117670 | 0.76 | TRPM8 (1.00) | TRPM8 | |
| SCHEMBL13064484 | 0.76 | MEN1 (0.78) | SMN1; SMN2LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL4514998 | 0.76 | MEN1 (0.52) | SMN1; SMN2LMNAKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| WO-2010125831-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094964-A1 | SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM5, TRPM6 | SMN1; SMN2 1501/4885LMNA 3339/4885ALDH1A1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.